Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease

• मुख्य लेखकों: Katie Lloyd (लेखक), Stamatia Papoutsopoulou (लेखक), Emily Smith (लेखक), Philip Stegmaier (लेखक), Francois Bergey (लेखक), Lorna Morris (लेखक), Madeleine Kittner (लेखक), Hazel England (लेखक), Dave Spiller (लेखक), Mike H. R. White (लेखक), Carrie A. Duckworth (लेखक), Barry J. Campbell (लेखक), Vladimir Poroikov (लेखक), Vitor A. P. Martins dos Santos (लेखक), Alexander Kel (लेखक), Werner Muller (लेखक), D. Mark Pritchard (लेखक), Chris Probert (लेखक), Michael D. Burkitt (लेखक), The SysmedIBD Consortium (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: The Company of Biologists, 2020-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Inflammatory bowel diseases (IBDs) cause significant morbidity and mortality. Aberrant NF-κB signalling is strongly associated with these conditions, and several established drugs influence the NF-κB signalling network to exert their effect. This study aimed to identify drugs that alter NF-κB signal...